Goodwin advised Relay Therapeutics on the completion of its $400 million Series C financing round. Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics’ long-term strategy.
Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, completed its $400 million Series C financing.
Relay Therapeutics combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology.
The integration of these disparate disciplines, tools and cultures enables Relay Therapeutics to overcome challenges that prior attempts have failed to solve and to design therapies against validated but previously intractable targets. Relay Therapeutics’ initial discovery programs in cancer have led to the development of highly selective inhibitors of disease-causing proteins in genomically defined patient populations.
The Series C financing was led by the SoftBank Vision Fund and included participation from additional new investors including Foresite Capital, Perceptive Advisors and Tavistock Group. Existing investors GV, Casdin Capital, BVF Partners, EcoR1 Capital, Alexandria Venture Investments, and an affiliate of D.E. Shaw Research also participated in the round.
Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics’ long-term strategy. It will support the expansion of the company’s discovery efforts, advance existing programs in to the clinic and bolster its broad platform and diverse team.
The Goodwin team was led by partner William Collins (Picture) and included partners Mitchell Bloom, Janet Andolina, Paul Jin, Richard Matheny and Victoria Elman; counsels Sonita Bennitt, Todd Hahn and Jacob Osborn; and associates Shoaib Ghias, Gabriela Morales-Rivera, Jason Goldfarb and Leslie Jaw and Matthew Wheatley.
Involved fees earner: Janet Andolina – Goodwin Procter; Sonita Bennitt – Goodwin Procter; Mitchell Bloom – Goodwin Procter; William Collins – Goodwin Procter; Victoria Elman – Goodwin Procter; Shoaib Ghias – Goodwin Procter; Jason Goldfarb – Goodwin Procter; Todd Hahn – Goodwin Procter; Paul Jin – Goodwin Procter; Richard Matheny – Goodwin Procter; Gabriela Morales-Rivera – Goodwin Procter; Jacob Osborn – Goodwin Procter; Matthew Wheatley – Goodwin Procter;
Law Firms: Goodwin Procter;
Clients: Relay Therapeutics, Inc.;